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INTRODUCTION
Today in the United States there is a high demand and
1
correspondingly a huge market for dietary supplements.
Accordingly, any regulatory policy in the area of dietary supplements
2
has the potential to affect a large portion of the population. About
sixty percent of Americans take dietary supplements in one form or
3
another. The results of a recent American Dietetic Association
survey indicate that approximately forty percent of adults take herbal
remedies and over eighty percent use vitamin and mineral
4
supplements. Yet, herbal supplements are potentially dangerous
5
when taken alone, or in combination with prescription drugs. For
example, ginkgo biloba has been linked to excessive bleeding and
6
stroke.
A recent survey found that twelve percent of herbal
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1
See Arthur A Levin, RX News: Dietary Supplement Safety Concerns, HEALTHFACTS,
June 2001, available at http://www.findarticles.com/cf_0/m0815/2001_June/75286
633/print.jhtml (on file with author).
2
Department of Health and Human Services, Office of the Inspector General,
Adverse Event Reporting for Dietary Supplements: An Inadequate Safety Valve (Apr. 2001),
available at http://oig.hhs.gov/oei/reports/oei-01-00-00180.pdf (on file with author)
[hereinafter HHS Report].
3
Id.
4
Jacqueline Stenson, The Herbal Frontier: The Promise and Peril of Supplements, at
http://www.msnbc.com/news/522365.asp (last visited Apr. 7, 2002) (on file with
author).
5
See infra note 46.
6
See HHS Report, supra note 2. The HHS Report noted that the FDA
commissioner stated, “[a] small but disturbing number of these products have a
potential for harm or bear unsupported claims. In this context, a rapidly expanding
industry and a changing demographic of consumers eager to manage their own
health care needs provide a significant regulatory challenge.” Id. at 7.
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supplement consumers experience side effects from these products.
Prior to the passage of the Dietary Supplement Health and
8
Education Act (“DSHEA”), the Food and Drug Administration
9
(“FDA”) had significantly more control over dietary supplements. At
that time, the FDA categorized dietary supplements as either drugs or
10
food additives, both of which require approval before marketing.
The DSHEA altered this scheme by taking dietary supplements out of
11
the food additive category.
The DSHEA categorized dietary
supplements as foods, a category over which the FDA has no power to
12
require clearance prior to marketing.

7

Id.
Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417,
108 Stat. 4325 (codified as amended in scattered sections of 21 U.S.C.).
9
Lauren J. Sloane, Herbal Garden of Good and Evil: The Ongoing Struggles of Dietary
Supplement Regulation, 51 ADMIN. L. REV. 323, 324 (1999).
10
Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary
Supplements: Examining Government Regulation Five Years After Enactment of the Dietary
Health and Education Act of 1994, 54 FOOD & DRUG L.J. 567, 568-69 (1999).
11
Id.
12
Pinco & Halpern, supra note 10, at 569. The FDA requires premarket approval
of food additives and for new drug application. HHS Report, supra note 2, at 6. The
FDA “is a scientific regulatory agency responsible for the safety of the nation’s
domestically produced and imported foods, cosmetics, drugs, biologics, medical
devices, and radiological products.” U.S. Food and Drug Administration, Center for
Food Safety and Applied Nutrition, Center for Food Safety and Applied Nutrition Overview,
at http://www.cfsan.fda.gov/~lrd/cfsan4.html (last updated Aug. 15, 2001) (on file
with author). The FDA’s principal function is consumer protection. Id. The FDA is
the “leading food and drug regulatory agency in the world,” and “is part of the
Executive Branch of the United States Government within the Department of Health
and Human Services (DHHS) and the Public Health Service (PHS).” Id. The
following table illustrates the differences between regulatory mechanisms for
different product classes as contained in the HHS Report:
8
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The DSHEA was passed in 1994, “largely in response to industry
13
pressure.”
The act amended the Food Drug & Cosmetic Act
14
(“FDCA”). Following the enactment of the DSHEA in 1994, which
decreased the FDA’s control over dietary supplement manufacturers,
15
the dietary supplement market increased tremendously. Since 1994,
dietary supplement sales have nearly doubled—from $8.6 billion to
16
17
$16 billion. This boom is due “in no small part” to the DSHEA.
The FDA Commissioner, Jane E. Henney, M.D., stated that the
purpose of the DSHEA was to grant the FDA power over dangerous
supplements without interfering with consumers’ ability to access
18
dietary supplements in general. The congressional findings relating
to the DSHEA are illustrative of the reasoning behind the enactment

Monograph
X
X
X
X
X
Drugs∗∗
New
Drug
X
X
X
X
X
X
X
Application
Drugs∗∗∗
∗
FDA does not collect or evaluate all adverse events on all conventional food. Excluded in this system
are the investigations FDA conducts following food-borne illness outbreaks.
∗∗
Monograph drugs are typically over-the-counter drugs that must adhere to specific safety standards set
out for each ingredient and do not undergo clinical testing.
∗∗∗
NDA is a new drug application that all prescription drugs and some over-the-counter drugs must
submit to FDA prior to market. This application must include data that demonstrates the safety and
efficacy of the product.

HHS Report, supra note 2, at 6.
13

Roseann B. Termini, Pharmanex, Inc. v. Shalala: A Wake Up Call For
Congress and a Not So Bitter Pill For the FDA, 26 OHIO N.U. L. REV. 269, 277
(2000).
14

Bruce H. Schindler, Where There’s Smoke There’s Fire: The Dangers of the
Unregulated Dietary Supplement Industry, 42 N.Y.L. SCH. L. REV. 261, 270 (1998). “The
Federal Food, Drug, and Cosmetic Act (FFDCA) authorizes the Food and Drug
Administration (FDA) to regulate foods, cosmetics, drugs and medical devices.”
Michigan State University, Institute for Environmental Toxicology, The Federal Food,
Drug, and Cosmetic Act, at http://www.iet.msu.edu/Regs/fedfoodact.htm (last
modified July 24, 1999) (on file with author). The purpose of the FDCA is to ensure
“that foods are pure and wholesome, safe to eat, and produced under sanitary
conditions; that cosmetics are safe and made from appropriate ingredients; that
drugs and devices are safe and effective for their intended uses; and, that all labeling
and packaging is truthful, informative, and not deceptive.” Id.
15
Iona N. Kaiser, Dietary Supplements: Can the Law Control the Hype?, 37 HOUS. L.
REV. 1249, 1250 (2000).
16
Stenson, supra note 4.
17
Pinco & Halpern, supra note 10, at 567.
18
Termini, supra note 13, at 281.
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19

of the DSHEA in its present form.
Among other things, the
congressional findings emphasized the enormity of the dietary
20
supplement industry. The findings further noted that although the
government should act against unsafe or adulterated products, the
government should not impose “unreasonable regulatory barriers”
for dietary supplements that are “safe within a broad range of
21
By removing some regulatory barriers, the DSHEA has
intake.”
made dietary supplements of all qualities widely available to
22
consumers. Thus, consumers face a larger risk of harm, perhaps
23
In
serious harm, from the effects of these dietary supplements.
allowing dietary supplements to enter the market without first
requiring some regulatory review, such as testing for the safety and
efficacy of the product, the consumer is, in all probability, subjected
to unknown health risks and effects.
This Comment will address the DSHEA, the risks its laxity
imposes on consumers, proposals to improve the current system and
reduce these risks, and will ultimately recommend a change in the
current scheme to protect consumers from these potentially
19

Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417,
sec. 2, 108 Stat. 4325, 4326 (Congressional Findings).
20
Id.
Regarding the enormity of the dietary supplement industry, the
congressional findings noted, in pertinent part:
. . . (9) national surveys have revealed that almost 50 percent of the
260,000,000 Americans regularly consume dietary supplements of
vitamins, minerals, or herbs as a means of improving their nutrition;
(10) studies indicate that consumers are placing increased reliance on
the use of nontraditional health care providers to avoid the excessive
costs of traditional medical services and to obtain more holistic
consideration of their needs; . . . ; (12)(A) the nutritional supplement
industry is an integral part of the economy of the United States;
(12)(B) the industry consistently projects a positive trade balance; and
(12)(C) the estimated 600 dietary supplement manufacturers in the
United States produce approximately 4,000 products, with total annual
sales of such products alone reaching at least $4,000,000,000 . . . .
Id.
21
Id. The Congressional Findings provided, in pertinent part, that:
. . . (13) although the Federal Government should take swift action
against products that are unsafe or adulterated, the Federal
Government should not take any actions to impose unreasonable
regulatory barriers limiting or slowing the flow of safe products and
accurate information to consumers; (14) dietary supplements are safe
within a broad range of intake, and safety problems with the
supplements are relatively rare; and (15)(A) legislative action that
protects the right of access of consumers to safe dietary supplements is
necessary in order to promote wellness . . . .
Id.
22
Pinco & Halpern, supra note 10, at 568.
23
See id.
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dangerous and highly available dietary supplements. In Part I, this
Comment discusses the DSHEA as it operates today and the FDA’s
power under the present regulatory scheme. Part II addresses special
cases in which the courts have accepted FDA’s efforts to exclude
street drugs, certain ingredients and other products from being
considered dietary supplements. Part III describes some of the
legislative actions taken by the states in reaction to the lax federal
scheme. The Comment concludes in Part IV, analyzing a range of
possible alternatives and changes to the DSHEA, and proposing a
solution to help remedy the dangers created by the current DSHEA
scheme without requiring pre-market clearance. This solution
involves the utilization and expansion of present efforts, in addition
to three changes which would require legislative action: shifting the
burden of proving a product’s safety onto the manufacturer, granting
the FDA power to act against dietary supplements as a class rather
than individually, and granting prescription status to supplements
that are dangerous when taken in excess of the amount suggested on
the label, when likely to be used in this manner.
I. THE DSHEA
A. General Provisions
24

The DSHEA created a new definition for “dietary supplement.”
25
This broad definition includes a wide range of products. A “dietary
supplement,” as explained by the FDA’s official website,
•
is a product (other than tobacco) that is intended to
supplement the diet that bears or contains one or more of
the following dietary ingredients: a vitamin, a mineral, an
herb or other botanical, an amino acid, a dietary substance
for use by man to supplement the diet by increasing the
total daily intake, or a concentrate, metabolite, constituent,
extract, or combinations of these ingredients
• is intended for ingestion in pill, capsule, tablet, or liquid
form.
• is not represented for use as a conventional food or as the
sole item of a meal or diet.
• is labeled as a “dietary supplement.”
• includes products such as an approved new drug, certified
24

Sloane, supra note 9, at 326.
Laura A. Khatcheressian, Regulation of Dietary Supplements: Five Years of DSHEA,
54 FOOD & DRUG L.J. 623, 626 (1999).
25
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antibiotic, or licensed biologic that was marketed as a
dietary supplement or food before approval, certification,
or license (unless the Secretary of Health and Human
26
Services waives this provision).
Under the DSHEA, a dietary supplement is “adulterated” if it
27
falls under any one of three new standards. First, the DSHEA deems
a dietary supplement “adulterated” if any of its ingredients or the
supplement itself present “a significant or unreasonable risk of illness
or injury” when taken according to the directions on the label or
28
under normal use when no directions are provided. Second, if a
dietary supplement “pose[s] an imminent hazard to public health or
safety,” the DSHEA deems this product adulterated and allows the
Secretary of Health and Human Services (“Secretary”) to remove the
29
supplement from the market.
Lastly, if a dietary supplement
30
contains a “new dietary ingredient,” it is considered adulterated if
there exists insufficient information to reasonably assure the absence
31
of a “significant or unreasonable risk.”
The DSHEA defines a “new dietary ingredient” as an “ingredient
that was not marketed in the United States before October 15,
32
1994.” The DSHEA’s definition of “new” suggests that it excludes
dietary ingredients sold before October 15, 1994, even if marketed
33
for a different use.
If a manufacturer plans to sell a product
containing a “new dietary ingredient,” it must give the FDA seventyfive days notice and include information demonstrating that the

26

U.S. Food and Drug Administration Center for Food Safety and Applied
Nutrition, Dietary Supplement Health and Education Act of 1994, at http://vm.cfsan.fda.g
ov/~dms/dietsupp.html (Dec. 1, 1995) (on file with author) [hereinafter DSHEA
Website]. The exact statutory language is found in 21 U.S.C. section 321(ff). See 21
U.S.C. § 321(ff) (2002).
27
Meghan Colloton, Dietary Supplements: A Challenge Facing the FDA in Mad Cow
Disease Prevention, 51 AM. U. L. REV. 495, 526 (2002) (citing Dietary Supplement
Health and Education Act of 1994, Pub. L. No. 103-417, sec. 4, § 402(f), 108 Stat.
4325, 4328 (1994)); see also 21 U.S.C. § 342(f) (2002).
28
DSHEA Website, supra note 26; see also 21 U.S.C. § 342(f)(1)(A) (2002).
29
Colloton, supra note 27, at 526 (quoting Dietary Supplement Health and
Education Act of 1994, Pub. L. No. 103-417, sec. 4, § 402(f)(1)(C), 108 Stat. 4325,
4328 (1994)); see also 21 U.S.C. § 342(f)(1)(C) (2002).
30
21 U.S.C. § 350b(c) (1999). A “new dietary ingredient” is an ingredient that
was not present in a dietary supplement prior to October 15, 1994. Id.
31
Colloton, supra note 27, at 526; see also 21 U.S.C. § 342(f)(1)(B) (2002).
32
Stephen H. McNamara & A. Wes Seigner, Jr., FDA has Substantial and Sufficient
Authority to Regulate Dietary Supplements, 57 FOOD & DRUG L.J. 15, 20 (2002) (quoting
21 U.S.C. § 350b(c) (1999) (F.D.C.A. Subchapter IV)).
33
Margaret Gilhooley, Deregulation and the Administrative Role: Looking at Dietary
Supplements, 62 MONT. L. REV. 85, 119 (2001).
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ingredient can “reasonably be expected to be safe.” The law does
35
not, however, require FDA approval. Because there is no official
record of ingredients that were sold before October 15, 1994, the
manufacturer must determine whether a particular ingredient is
36
“new.” In addition, a dietary supplement is deemed adulterated if it
“is or contains a dietary ingredient that renders it adulterated under
paragraph (a)(1) under the conditions of use recommended or
37
suggested in the labeling of such dietary supplement.”
The FDA only has the power to limit the use of a specific dietary
supplement (provided there is no “new” ingredient) if the FDA
proves the supplement creates a “significant or unreasonable risk”
38
under the dosage specified on the label. Therefore, provided the
supplement does not contain a new ingredient, the FDA has no
39
power to stop a dietary supplement from placement on the market.
These supplements will be available to consumers until the FDA
shows that the supplement is a “significant or unreasonable risk,”
40
typically established by adverse event reports.
An adverse event is an event that may be linked to a product or
41
ingredient. The FDA has a system in effect to collect and review
42
Reporting
adverse event reports linked to dietary supplements.
these adverse events is completely voluntary, and these adverse events
are reported by “consumers, health professionals, and manufacturers
through a variety of sources, including State health departments,
Poison Control Centers, direct communication with individuals, and
MedWatch, a computerized reporting system used to monitor a
43
variety of FDA-regulated products.” In effect, the statute provides
little protection to consumers until actual instances of harm have

34

DSHEA Website, supra note 26.
Ilene Ringel Heller, Functional Foods, Regulatory and Marketing Developments, 56
FOOD & DRUG L.J. 197, 198-99 (2001).
36
See id.
35

37

21 U.S.C. § 342(f)(1)(D) (2002). 21 U.S.C. section 342(a)(1)
addresses particular circumstances in which a food will be deemed
adulterated. See 21 U.S.C. § 342(a)(1) (2002). For example, it states that a
food is deemed adulterated if it “bears or contains any poisonous or
deleterious substance which may render it injurious to health” or if it
“consists in whole or in part of any filthy, putrid, or decomposed substance,
or if it is otherwise unfit for food.” Id.
38
39
40
41
42
43

21 U.S.C. § 342(f) (2002).
See id.
Colloton, supra note 27, at 529-30.
HHS Report, supra note 2, at 1.
Id.
Id.
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occurred or until a basis exists to project that actual instances of
44
harm will occur. Additionally, the DSHEA placed the burden of
45
proving a supplement unsafe or adulterated on the FDA. With this
lax statutory regime, potentially dangerous supplements are widely
46
available to the public. These supplements may have serious side
47
effects and may interact with other medications.
For example,
ginkgo biloba, a dietary supplement, is a blood thinner that may
48
cause excessive bleeding, and may lead to stroke.
44
45

21 U.S.C. § 342(f) (2002); see also Colloton, supra note 27, at 528-34.
Colloton, supra note 27, at 527.

46
See Colloton, supra note 27, at 497. Some of the potential dangers of
dietary supplements are worth noting to demonstrate the need for stricter
regulation. Ginkgo biloba, a popular herbal supplement, can cause
excessive bleeding. Levin, supra note 1. Ginkgo biloba is sold in varying
contents and amounts of active ingredients; to date, there is no specific daily
amount established as safe. NIH News Release, NIH Awards Multicenter Study
on Ginkgo Biloba for Dementia, at http://www.nih.gov/news/pr/sept99/ncca
m-30.htm (Sept. 30, 1999) (on file with author). “Some recent cases imply
that daily use of gingko biloba extracts may cause side effects, such as
excessive bleeding, especially when combined with daily use of aspirin.” Id.
There is an additional risk in taking ginkgo biloba with anticoagulants and
antiplatelet medications. Melanie Johns Cupp, Herbal Remedies: Adverse Effects
and Drug Interactions, AM. FAM. PHYSICIAN (Mar. 1, 1999), available at
http://www.aafp.org/afp/990301ap/ 1239.html (on file with author).

There are dangers even in conventional dietary supplements such as vitamin A.
See Levin, supra note 1; see also Associated Press, Vitamin A linked to hip fracture,
available at http://www.msnbc.com/news/680496.asp (Jan. 1, 1999) (on file with
author). High doses of vitamin A have been linked to birth defects, and recently
have been associated with hip fractures. Id. Garlic may dangerously interfere with
AIDS drugs. Associated Press, Garlic Pills may block AIDS drugs, available at www.msnb
c.com/news/668796.asp (Dec. 6, 2001) (on file with author).
Ephedra is a popular dietary supplement that is taken by approximately 12
million Americans. Stenson, supra note 4. Ephedra is associated with cardiovascular
problems such as high blood pressure, strokes, and heart attacks, in addition to
being associated with seizures. Id. Furthermore, Ephedra has caused 20-30 deaths.
Levin, supra note 1.
St. John’s Wort should be avoided by individuals taking antidepressants. Cupp,
supra note 46. Additionally, St. John’s Wort can interfere with oral birth control pills,
AIDS drugs, cancer drugs, and treatments to help with organ transplants. Stenson,
supra note 4.
Taking ginseng can cause a decreased response to warfarin, commonly known
by its brand name, Coumadin. Cupp, supra note 46. Warfarin is generally prescribed
to prevent the formation or movement of blood clots. See http://www.fyipharmacist.
com/monographs/coumadin.html (last visited Apr. 9, 2002) (on file with author).
It has not yet been proven, but doctors caution that Androstendione may cause
side effects similar to those of steroids, such as liver cancer. Crossman, infra note
196, at 632. Creatine, when taken regularly, is presumed by some physicians to cause
renal failure. Id. The preceding is just an abbreviated list of the potential hazards of
dietary supplements.
47
See supra note 46 (describing potential side effects of dietary supplements).
48
HHS Report, supra note 2, at 7.
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With the exception of new dietary ingredients, manufacturers
have no obligation to provide the FDA with any evidence to prove the
49
safety or efficacy of their product. Additionally, manufacturers are
not required to register their product or company information with
50
the FDA.
Presently, there are no FDA regulations that govern the
51
manufacture of dietary supplements.
The nature of some herbs
52
makes the absence of FDA regulation especially dangerous. The
potency of an herb depends on many different factors, such as soil,
sunlight, temperature, season, age and structure of the plant, and the
53
post-harvesting method used.
Because of these factors, herbal
remedies can differ significantly in quality and strength of
54
ingredients.
Herbal remedies frequently contain amounts of
ingredients that differ, sometimes significantly, from the amount
55
listed on the label.
The DSHEA gave the Secretary power to enact regulations that
impose good manufacturing practices on dietary supplement
56
manufacturers.
The FDA plans to create these “good
manufacturing practices” (“GMPs”) regulations for the dietary
57
supplement industry. These regulations would work to ensure the
“identity, purity, quality, strength and composition of dietary
58
supplements.”
Accordingly, the regulations should help prevent
some of the dangers associated with dietary supplements, such as
when prescription medications are illegally added into the
supplements, or when supplements are contaminated with metals
59
and pesticides. Additionally, GMPs would allow the FDA to confirm
60
ingredient amounts contained in the product. Until the FDA issues

49

U.S. Food and Drug Administration Center for Food Safety and Applied
Nutrition, Overview of Dietary Supplements, at http://vm.cfsan.fda.gov/~dms/dsoview.html#what (Jan. 3, 2001) (on file with author) [hereinafter FDA Overview
Website].
50
Id.
51
FDA Overview Website, supra note 49.
52
See Linda G. Tolstoi, Herbal Remedies: Buyer Beware, NUTRITION TODAY, July 2001,
available at http://www.findarticles.com/cf_0/m0841/4_36/77841951/p1/article.jht
ml?trm=Tolstoi (on file with author).
53
Id.
54
Id.
55
Stenson, supra note 4.
56
21 U.S.C. § 342 (g)(2) (2002).
57
FDA Overview Website, supra note 49.
58
Id.
59
See Stenson, supra note 4; see also HHS Report, supra note 2, at 23.
60
HHS Report, supra note 2, at 23.
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these regulations, the manufacturer will continue to have power over
61
its own production of dietary supplements.
B. FDA’s Supervision of the Dietary Supplement Industry
The DSHEA places dietary supplements within the food category
and the FDA’s Center for Food Safety and Applied Nutrition
62
(“CFSAN”) is responsible for the oversight of dietary supplements.
To police the dietary supplement market for illegal products, the
FDA utilizes the Internet, results from inspections conducted on the
manufacturers and distributors, complaints and adverse events
63
reported to the FDA, and the occasional product laboratory test.
The FDA considers a product illegal when it exhibits false or
64
misleading claims, or when the product is deemed unsafe.
Because manufacturers are generally not required to get FDA
approval, nor are they required to register their products with the
FDA, the FDA does not have a record of the supplements presently
65
on the market.
If a consumer desires more information on a
66
particular product on the market, the FDA will not possess it. To
obtain this additional information, the consumer must turn to the
67
product manufacturer.
A recent U.S. Department of Health and Human Services
(“HHS”) study concluded that the FDA’s method of supervision
68
regarding dietary supplements is inadequate. The report stated that
the FDA learns of less than one percent of the adverse events linked
69
to dietary supplement use. The study opined that this low number

61

See FDA Overview Website, supra note 49. 21 C.F.R., pt. 111 is titled
“CURRENT
GOOD
MANUFACTURING
PRACTICE
FOR
DIETARY
SUPPLEMENTS” and states that its authority comes from 21 U.S.C. sections 321, 342
(2002), and 371 (1999). 21 C.F.R., pt. 111 (2002). As of yet, there appears to be
only one provision in this part, and it addresses the packaging of iron-containing
dietary supplements. See 21 C.F.R. § 111.50 (2002). This section establishes that for
certain iron-containing supplements to be in accordance with good manufacturing
practices, the supplements must be in unit-dose packaging. Id. The provision goes
on to define “unit-dose packaging,” and to exempt certain classes of iron-containing
supplements. Id.
62
FDA Overview Website, supra note 49.
63
Id.
64
Id.
65
Id.
66
Id.
67
Id.
68
EXECUTIVE BRIEFING, BNA’S HEALTH CARE DAILY REPORT (Apr. 24, 2001)
[hereinafter EXECUTIVE BRIEFING]; see also HHS Report, supra note 2.
69
HHS Report, supra note 2.
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70

may be due to various factors. The study noted, for example, that
consumers may presume dietary supplements are safe, and,
additionally, that consumers often take supplements without medical
71
supervision. The report observed that the FDA was unsuccessful in
obtaining the necessary information to properly look into the adverse
72
events reported.
For example, in the period between 1994 and
1999, the FDA failed to obtain medical records for fifty-eight percent
73
of the adverse event reports it was to investigate. The report listed
other factors that illustrate how the oversight is inadequate, including
the FDA’s inability to identify the ingredients in thirty-two percent of
the supplements involved in the adverse event reports, the FDA’s
failure to possess labels for seventy-seven percent of the supplements
referred to in the reports, and the FDA’s failure to obtain sixty-nine
percent of the supplement samples it requested from
74
manufacturers.
The report also criticized the use of the FDA’s
website as its principal means for disseminating information to
75
consumers. Among the reasons for this criticism was the fact that
the FDA seldom updates the website and, therefore, the information
76
contained in the website may be outdated.
C. Overview of Permissible Claims Under DSHEA
The DSHEA also addresses the claims that dietary supplement
77
manufacturers place on their products. The statute clarifies what
78
types of claims are permissible for dietary supplement labels. This
comment gives only a broad overview of the DSHEA’s restrictions on
permissible claims; however, it is important to address the permissible
claims because the DSHEA arguably allows manufacturers to
dangerously lead consumers to believe a certain dietary supplement
79
will, for example, help treat a certain disease. The DSHEA does
permit various statements to be placed on dietary supplement labels,
70

Id.
Id.
72
EXECUTIVE BRIEFING, supra note 68.
73
HHS Report, supra note 2.
74
Id.
75
Id. at 17.
76
EXECUTIVE BRIEFING, supra note 68.
77
Khatcheressian, supra note 25, at 628.
Claims are the statements
manufacturers place on the labels of dietary supplements. See DSHEA Website, supra
note 26.
78
Kelly Ann Kaczka, From Herbal Prozac to Mark McGwire’s Tonic: How the Dietary
Supplement Health and Education Act Changed the Regulatory Landscape for Health
Products, 16 J. CONTEMP. HEALTH L. & POL’Y 463, 477-78 (2000).
79
Khatcheressian, supra note 25, at 637-38.
71
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however, it does not allow these claims to state that the dietary
supplement will “diagnose, prevent, mitigate, treat, or cure a specific
disease (unless approved under the new drug provisions of the
80
[Federal Food, Drug, and Cosmetic] Act).” There are three basic
types of claims that are legally permissible: “health claims,
81
structure/function claims, and nutrient content claims.” Different
82
Prior regulations allowed
claims have different requirements.
health claims and nutrient content claims; the DSHEA added the
83
category of structure/function claims.
The DSHEA permits claims asserting that a “dietary ingredient”
impacts “the structure or function of the body” (“structure/function
84
claims”). A permissible type of structure/function claim describes
the “general well-being from consumption of a nutrient or dietary
85
ingredient.”
Another
generally
acceptable
type
of
structure/function claim involves assertions that dietary supplement
86
Manufacturers
use is beneficial to a nutrient deficiency disease.
have the responsibility of substantiating these structure/function
87
claims; however, prior approval by the FDA is not required. The
DSHEA does not define “substantiation,” and does not require
88
submission to the FDA. When making structure/function claims,
manufacturers need only include the following disclaimer on the
80

DSHEA Website, supra note 26.
U.S. Food and Drug Administration, Center for Food Safety and Applied
Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements, Claims
that Can be Made for Conventional Foods and Dietary Supplements, at http://www.cfsan.fd
a.gov/~dms/hclaims.html (last revised Oct. 2001) (on file with author) [hereinafter
FDA Claims Website].
82
FDA Overview Website, supra note 49.
83
See FDA Claims Website, supra note 81.
84
Gilhooley, supra note 33, at 95-96 (citing 21 U.S.C. § 343(r)(6)(A) (2002)); see
also 21 C.F.R. § 101.93 (2001). 21 C.F.R. section 101.93(f) states that dietary
supplement labels may contain statements that “describe the role of a nutrient or
dietary ingredient intended to affect the structure or function in humans or that
characterize the documented mechanism by which a nutrient or dietary ingredient
acts to maintain such structure or function.” 21 C.F.R. § 101.93(f) (2001). This
provision specifies that dietary supplement labels cannot make disease claims, as
defined by 21 C.F.R. section 101.93(g), and if such claims are made, the product will
be regulated as a drug. Id.
85
Khatcheressian, supra note 25, at 628 (citing 21 U.S.C. § 343(r)(6) (2002)); see
also FDA Claims Website, supra note 81 (listing this type of claim as allowed under
the category of structure/function claims).
86
Khatcheressian, supra note 25, at 628; see also FDA Claims Website, supra note
81. If making such a claim, however, a manufacturer must include information on
how prevalent this deficiency disease is in the United States. FDA Claims Website,
supra note 81.
87
Gilhooley, supra note 33, at 95; see also FDA Claims Website, supra note 81.
88
Khatcheressian, supra note 25, at 628.
81
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label of the dietary supplement: “This statement has not been
evaluated by the Food and Drug Administration. This product is not
89
intended to diagnose, treat, cure, or prevent any disease.” However,
“[t]his system allows manufacturers of dietary supplements to hint
that a product will help a disease without actually saying so (e.g.,
‘lowers cholesterol’ is reasonably understood by consumers to mean
90
that the product treats the illness of high cholesterol).”
91
Health claims are also permissible. These claims “describe a
relationship between a food substance and a disease or health-related
92
condition.” There are two different avenues under which the FDA
93
evaluates these claims to determine whether they are permissible.
94
Under the first avenue, the FDA reviews scientific literature. Here,
if the FDA finds “significant scientific agreement” as to the particular
95
nutrient/disease relationship, the claim is allowed.
If there is
insufficient scientific evidence to obtain permission through the first
96
avenue, a second avenue is available to obtain this permission. The
second avenue requires the FDA to “allow appropriately qualified
97
health claims that would be misleading without such qualifications.”
These claims need only have sufficient scientific evidence such that
98
there is more proof for the relationship than against it. The United
States Circuit Court for the District of Columbia approved this
99
second means of evaluating a claim in Pierson v. Shalala, in a
decision “relating to supplements on constitutional grounds based on
100
commercial free speech.”
D. Research Efforts
The DSHEA provided that the HHS Secretary should create an
101
Office of Dietary Supplements (“ODS”).
The DSHEA mandated
the formation of the ODS to establish a body in charge of obtaining

89

Id. (quoting 21 U.S.C. § 343(r)(6)(C)); see also FDA Claims Website, supra note

90

Khatcheressian, supra note 25, at 637-38.
FDA Claims Website, supra note 81.
Id.
Id.
Id.
Id.
Id.
FDA Claims Website, supra note 81.
Id.
164 F.3d 650, 657 (D.C. Cir. 1999).
Gilhooley, supra note 33, at 110.
Sloane, supra note 9, at 328.

81.
91
92
93
94
95
96
97
98
99
100
101

424

SETON HALL LAW REVIEW

Vol. 33:411

information on dietary supplements through scientific research and
102
to subsequently distribute the information. On November 27, 1995,
the ODS was formally established within the National Institutes of
103
Health (“NIH”).
The two primary goals of the ODS are: “(1) to
research how dietary supplements can improve our nation’s
healthcare system; and (2) to encourage the study of dietary
104
supplements.”
The ODS is also responsible for advising federal
105
agencies on dietary supplement matters.
The ODS, however, has
106
no role in the regulation of dietary supplements.
At the start of 2000, the FDA announced its Ten Year Plan
107
setting forth the CFSAN’s “overall dietary supplement strategy.”
Section V of this Ten Year Plan set forth CFSAN’s goals in science
108
In an effort to initiate these objectives, the FDA
and research.
presented a two-year, $1 million grant to the National Academy of
Sciences for the purpose of creating a framework for evaluating

102

Id. at 328, 337.
National Institutes of Health Office of Dietary Supplements, About ODS, at
http://ods.od.nih.gov/about/started.html (last visited Oct. 20, 2002) (on file with
author). Specifically, the ODS was established “within the Office of Disease
Prevention, Office of the Director, at the National Institutes of Health. Bernadette
M. Marriott, Ph.D. was appointed Director of the ODS. The current Director is Paul
M. Coates, Ph.D.” Id.
104
Sloane, supra note 9, at 328.
105
Id.
106
Id. at 337.
107
LETTER FROM DIRECTOR, U.S. FOOD AND DRUG ADMINISTRATION, CENTER FOR
FOOD SAFETY AND APPLIED NUTRITION, DIETARY SUPPLEMENT STRATEGY (TEN YEAR PLAN)
(Jan. 2000), available at http://vm.cfsan.fda.gov/~dms/ds-strat.html (on file with
author) [hereinafter TEN YEAR PLAN]. “The Center for Food Safety and Applied
Nutrition, known as CFSAN, is one of six product-oriented centers, in addition to a
nationwide field force, that carry out the mission of the Food and Drug
Administration (FDA).” U.S. Food and Drug Administration, Center for Food Safety
and Applied Nutrition, Center for Food Safety and Applied Nutrition Overview, at
http://www.cfsan.fda.gov/~lrd/cfs an.html (last updated Aug. 15, 2001) (on file with
author). “CFSAN, in conjunction with the Agency’s field staff, is responsible for
promoting and protecting the public’s health by ensuring that the nation’s food
supply is safe, sanitary, wholesome, and honestly labeled, and that cosmetic products
are safe and properly labeled.” Id.
108
Id. One of the goals set out by Section V is to “enhance research/science
capabilities,” including strengthening the science base by ensuing “sound sciencebased program for all dietary supplement review and develop a core of well-trained,
multidisciplinary scientists in support of supplement review and research.” Id.
Another goal mentioned in Section V is strengthening research efforts by working
with the “assistance of a nationally recognized organization” to create a “broad
research agenda and needs assessment framework to implement priority-based
research for dietary supplement issues.” Id. Section V additionally sets out the goals
related to, among other things, dietary supplement ingredient reviews, consumer
research, marketplace research, and the adverse event monitoring system. Id.
103
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109

herbs.
More recently, on July 25, 2002, the National Institute of
Environmental Health Sciences (“NIEHS”) and the ODS, both part
of the NIH, announced a $6 million, five-year grant to create a
research center to study Echinacea and Hypericum, known as St.
110
John’s Wort.
Echinacea and Hypericum are botanical dietary
111
supplements. This new center, along with established NIH centers
located at universities around the country, “[is] expected to greatly
advance the scientific base of knowledge on botanicals, including
112
issues of their effectiveness, safety, and biological action.”
II. SPECIAL SITUATIONS LIMITING SCOPE OF DIETARY SUPPLEMENTS
This section will focus on two recent court decisions: United States
113
v. Undetermined Quantities of Articles of Drug and Pharmanex v.
114
Shalala. In both of these cases, the courts had the power to evaluate
the FDA’s interpretation and application of law, with the potential to
115
either reduce or increase the FDA’s authority. Both courts ruled in
116
favor of the FDA.
These cases expanded the FDA’s power by
allowing increased control, at least in these special circumstances,
117
over dietary supplements. In these special cases, the court accepted
an FDA position narrowing the meaning of “dietary supplement,”
118
thereby promoting safety.
There is a great deal of controversy concerning products that
claim to be dietary supplements while advertising that they act as
119
120
natural alternatives to illicit drugs. In Undetermined Quantities, for
example, some of the products at issue were called “Rave X,”

109

Stenson, supra note 4.
NIH News Release, NIH Funds Botanical Center in Iowa to Study Health Effects of
Echinacea and St. John’s Wort, at http://www.nih.gov/news/pr/jul2002/niehs-25.htm
(July 25, 2002) (on file with author).
111
Id.
112
Id.
113
145 F. Supp. 2d 692 (D. Md. 2001).
114
221 F.3d 1151 (10th Cir. 2000).
115
See Undetermined Quantities, 145 F. Supp. 2d 692; Pharmanex, 221 F.3d 1151.
116
See Undetermined Quantities, 145 F. Supp. 2d 692; Pharmanex, 221 F.3d 1151.
117
See Undetermined Quantities, 145 F. Supp. 2d 692; Pharmanex, 221 F.3d 1151.
118
See Undetermined Quantities, 145 F. Supp. 2d 692; Pharmanex, 221 F.3d at 1151.
119
See, e.g., Cary Elizabeth Zuk, Herbal Remedies are Not Dietary Supplements: A
Proposal for Regulatory Reform, 11 HASTINGS WOMEN’S L.J. 29, 43-46 (2000) (describing
the marketing of, and the FDA’s reaction to, a product called “Herbal Ecstasy,” and
its claims of, among other things, “euphoria, increased sexual sensations, [and]
heightened awareness”).
120
Undetermined Quantities, 145 F. Supp. 2d at 696.
110
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“Hashanna Oil,” “Herbal Hash,” and “Herbal Opium.”
The
122
defendants claimed these products were dietary supplements. The
FDA disagreed, categorizing these products as “street drug
alternatives,” and concluded that they were misbranded and
123
unapproved drugs. This characterization meant the products were
124
illegal as violative of the Food, Drug, & Cosmetic Act (“FDCA”).
The FDA seized the products and the Unites States brought action to
seek an order of condemnation as well as permanent injunctive
125
relief. The FDA relied on its own “Guidance for Industry on Street
126
127
Drug Alternatives” (“the Guidance”) in making its determination.
The Guidance declared that these street drug alternatives were not
dietary supplements, but instead were unapproved new and
128
misbranded drugs.
The Undetermined Quantities court agreed with
the defendants that the Guidance was not binding because it was not
a substantive rule, but rather an interpretive statement of the FDA’s
129
position. Yet, the court did acknowledge that the Guidance was to
130
be accorded some deference. The court noted that interpretations
are entitled to some deference in the respect that they have the
131
“power to persuade.”
The court found that the Guidance was
132
“highly persuasive in light of the text and purposes of the FDCA.”
The court refused “to carve out a statutory loophole for drug
manufacturers attempting to profit from the illegal drug epidemic by
121

Id.
Id.
123
Id.
124
Id.
125
Id.
126
Guidance for Industry on Steet Drug Alternatives; Availability, 65 Fed. Reg. 17,
512 (Dep’t of Health and Human Servs., FDA Apr. 3, 2000). This guidance, in
pertinent part, stated the following:
[t]his guidance is intended to inform industry and the public that FDA
considers any product that is promoted as a street drug alternative to
be an unapproved new drug and a misbranded drug in violation of
sections 505 and 502 of the act (21 U.S.C. §§ 355, 352). Such violations
may result in regulatory action, including seizure and injunction.
Moreover, FDA is also aware that some of these street drug alternatives
are being promoted as dietary supplements. FDA does not consider
street drug alternatives to be dietary supplements because they are not
intended to supplement the diet.
Id.
127
Id.
128
Undetermined Quantities, 145 F. Supp. 2d at 697.
129
Id.
130
Id.
131
Id.
132
Id.
122
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masquerading potentially dangerous substances as legitimate dietary
133
supplements.”
The court noted that the definition of “dietary
supplement” requires that the product be labeled as a dietary
134
Because many of the defendants’ products at issue
supplement.
were not labeled as dietary supplements, they could not be regarded
135
as dietary supplements. The court continued its analysis, however,
to determine whether both these supplements, as well as those
136
labeled as dietary supplements, fit within the definition of “drug.”
The court found that the term “drug” is defined by the FDCA as
“articles (other than food) intended to affect the structure or any
137
function of the body of man or other animals.”
Therefore, the
court posited, to be a “drug,” the product must both actually and
138
intentionally “affect the structure or any function of the body.” In
determining whether a product intends to have such an effect, the
court emphasized that it is crucial to look at the claims and labeling
139
made by the manufacturer. The court asserted that the products in
140
question did purport to affect the mind.
Concluding that the
products intended “to affect the function and structure of the mind
by elevating the psychological condition of users and therefore the
141
products were ‘drugs,’”
the court granted summary judgment to
the government and ruled that these “street drug alternatives” were
142
in fact new drugs in violation of the FDCA. The court recognized
the danger of manufacturers attempting to classify products as dietary
143
supplements.
Manufacturers would presumably want their
products to be classified as dietary supplements, as in the present
144
case, because of the relaxed regulations.
Fortunately, the court
stepped in and disallowed the manufacturers from taking advantage
145
of the DSHEA’s loose requirements.
133

Id.
Undetermined Quantities, 145 F. Supp. 2d at 698.
135
Id.
136
See id. In United States v. Ten Cartons, the court ruled that a particular product
can qualify both as a “dietary supplement” and as a “drug.” 72 F.3d 285 (2d Cir.
1995).
137
Undetermined Quantities, 145 F. Supp. 2d at 698 (citing 21 U.S.C. §
321(g)(1)(C)).
138
Id.
139
Id.
140
Id.
141
Id. at 700.
142
Id. at 692.
143
See Undetermined Quantities, 145 F. Supp. 2d at 692.
144
Id. at 696-97.
145
See id. at 692.
134
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This case demonstrates how courts can help to increase the
146
FDA’s current power over dietary supplements. Interpretations can
147
significantly affect regulatory policy, and in deferring to the FDA
regarding their more expansive interpretations, courts may be able to
assist in expanding power over the dietary supplement industry. The
court recognized the danger inherent in the defendants’ attempt to
circumvent anti-drug laws and the FDCA, and appears to have
148
reached its conclusion in part to prevent these potential dangers.
149
In Pharmanex, the plaintiff challenged the FDA’s interpretation
of 21 U.S.C. §321(ff)(3)(B)—part of the FDCA as amended by the
150
DSHEA—which defines the term “dietary supplement.”
This
statute states that the term “dietary supplement” does not include
151
The FDA’s argument was that the
articles approved as new drugs.
statutory language stating, “an article that is approved as a new drug,”
152
applies to both finished products and active ingredients.
After
analyzing Pharmanex’s argument that the plain meaning cannot
support such an interpretation, looking at the legislative history, and
examining the policies of the DSHEA and the FDCA, the court
concluded that the language was “sufficiently ambiguous to merit
153
Chevron deference.”
The court, therefore, held that the FDA’s
interpretation as applying to both active ingredients and to finished
products was not “arbitrary, capricious, or manifestly contrary to the
154
statute.”
This holding allowed the FDA to prevent Pharmanex from
146

See id.
Daniel B. Rodriquez, The Presumption of Reviewability: A Study in Canonical
Construction and Its Consequences, 45 VAND. L. REV. 743, 766-67 (1992) (stating that
“[b]y developing and applying the canons of construction, courts can recover from
the political branches a certain amount of power over the process of interpretation
and, as a consequence, preserve their role in implementing and making regulatory
policy”).
148
See Undetermined Quantities, 145 F. Supp. 2d at 697.
149
Pharmanex v. Shalala, 221 F.3d 1151 (10th Cir. 2000).
150
Id. at 1153.
151
Id. at 1154.
152
Id.
153
Id. The U.S. Supreme Court first articulated the Chevron deference test in
Chevron U.S.A., Inc. v. Nat’l Res. Def. Council, 467 U.S. 837 (1984). The Chevron Court
set forth the standard to review an agency’s construction of a statute. Id. The first
inquiry, in reviewing an agency’s construction of a statute, is whether “Congress has
directly spoken to the precise question at issue.” Id. If the answer to this inquiry is
yes, then Congress’s intent must prevail. Id. If, however, the answer to that inquiry is
no, then the court must evaluate only whether “the agency’s answer is based on a
permissible construction of the statute” in order to allow the agency’s interpretation
to stand. Id.
154
Pharmanex, 221 F.3d at 1160.
147
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marketing its product as a dietary supplement without FDA approval
because the supplement contained an active ingredient, mevinolin,
155
which the FDA deemed to be a drug.
This case illustrates the
realistic danger that dietary supplement manufacturers may
formulate products that are categorized as dietary supplements, yet
imitate drugs—allowing manufacturers to avoid the stricter
156
regulatory framework that applies to drugs. The FDA, as a result of
this case, can look not only at finished products as a whole to
determine their status as a dietary supplement, but also at individual
ingredients within a product to see if any ingredients are properly
157
characterized as drugs. This decision gives the FDA the authority to
prevent manufacturers from placing substances that would be
characterized as drugs if taken alone into a formula of other
ingredients to gain the status and looser regulations of dietary
158
supplements.
III. THE ROLE OF THE STATES
A. State attempts to increase control over dietary supplements within
their borders
Some states have enacted statutes to increase control over a
159
certain dietary supplement—ephedrine.
This Comment addresses
various legislative steps states have taken to protect their citizens from
the harms presented by ephedrine. These legislative steps include

155

Id. at 1153.
See Termini, supra note 13, at 287.
157
Pharmanex, 221 F.3d at 1153.
158
Id.
159
HHS Report, supra note 2, at 28. A description of ephedra was given in the
HHS Report, and stated that
[e]phedrine alkaloids may be derived from plants (botanicals) or
synthesized chemically. The botanical form is generally derived from
Ephedra sinica, also known as ma huang, but it may come from other
botanical sources. The most common uses for supplements containing
botanical ephedrine alkaloids are for losing weight and boosting
energy. . . . According to the FDA, between 1993, when it began a new
system to collect dietary supplement adverse event reports, and March,
2000, it received 1,173 adverse event reports associated with the use of
products that contain, or were suspected to contain, ephedrine
alkaloids. Many of these reports involved serious events, including
some deaths. . . . As of September 2000, FDA had not taken any action
to regulate ephedrine alkaloids, although during this time period many
States and industry groups have taken safety measures related to these
supplements.
Id.
156
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making ephedrine available only by prescription, prohibiting any
individual who is not a pharmacist from dispensing ephedrine, and
making it a criminal offense to sell ephedrine-containing products to
160
minors or individuals under seventeen years of age.
For example,
in Texas, a “person commits an offense if the person knowingly sells,
transfers, or otherwise furnishes a product containing ephedrine to a
161
person under 17 years of age,” with certain exceptions.
Florida
makes it necessary to obtain a prescription for products containing
162
ephedrine.
Tennessee, Louisiana, and Minnesota have statutes,
which provide that ephedrine-based products “may be dispensed only
upon prescription of a duly licensed practitioner authorized by the
163
laws of the state to prescribe prescription drugs.”
Ohio mandates
that consumers obtain ephedrine substances from pharmacists only,
with certain exceptions, and that consumers must be at least eighteen
164
years of age.
Virginia has a statute that makes it a Class 1
misdemeanor to “knowingly sell or otherwise distribute (without
prescription), to a minor, any pill, capsule, or tablet containing any
165
combination of caffeine and ephedrine sulfate.” Nebraska statutory
law imposes certain requirements for labeling on ephedrine
containing food and dietary supplements, and requires that a
160

See, e.g., TENN. CODE ANN. § 39-17-431 (1995); LA. REV. STAT. ANN. § 40:962.1
(West 1995); MINN. STAT. ANN. § 152.135 (West 1998); TEX. HEALTH & SAFETY CODE
ANN. § 431.022 (Vernon 2001); OHIO REV. CODE ANN. §§ 3719.41 (West 1999),
3719.44(K)(1) (West 2002); VA. CODE ANN. §§ 18.2 – 248.5(B) (Michie 2000); NEB.
REV. STAT. § 28-448 (2001).
161
TEX. HEALTH & SAFETY CODE ANN. § 431.022 (Vernon 2001). The prohibition
made in this statute does not apply if:
(1) the actor is: (A) a practitioner or other health care provider
licensed by this state who has obtained, as required by law, consent to
the treatment of the person to whom the product is furnished; or (B)
the parent, guardian, or managing conservator of the person to whom
the product is furnished; (2) the person to whom the product is
furnished has had the disabilities of minority removed for general
purposes under Chapter 31, Family Code; or (3) the product is a drug.
TEX. HEALTH & SAFETY CODE ANN. § 431.022 (Vernon 2001).
162
Jennifer Sardina, Note, Misconceptions and Misleading Information Prevail—Less
Regulation Does Not Mean Less Danger to Consumers: Dangerous Herbal Weight Loss
Products, 14 J.L. & HEALTH 107, 123-24 (2000).
163
TENN. CODE ANN. § 39-17-431 (1995); LA. REV. STAT. ANN. § 40:962.1 (West
1995); MINN. STAT. ANN. § 152.135 (West 1998).
164
Kaiser, supra note 15, at 1269; see also OHIO REV. CODE ANN. §§ 3719.41 (West
1999), 3719.44(K)(1) (West 2002). Ohio state law classifies ephedrine as a Schedule
V drug, which requires a prescription, except as provided by § 3719.44(K)(1). OHIO
REV. CODE ANN. § 3719.41 (West 1999). Section 3719.44(K)(1) lists specific products
that are not to be considered schedule V drugs, such as amesec capsules, Primatene
“M” and “P” formula tablets, and Vatronol nose drops. Id.
165
VA. CODE ANN. §§ 18.2 – 248.5(B) (Michie 2000).
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“prominent label securely affixed to each package” include certain
specific information such as the amount of ephedrine in milligrams
166
and a maximum dosage. Importantly, the statute also requires that
167
this label contain a specific warning.
B. Preemption
168

In Jones v. Rath Packing Co., the United States Supreme Court
described preemption law as occurring:
when Congress has “unmistakably . . . ordained,” that its
enactments alone are to regulate a part of commerce, state laws
regulating that aspect of commerce must fall. This result is
compelled whether Congress’ command is explicitly stated in the
statute’s language or implicitly contained in its structure and
169
purpose.

Therefore, preemption may be either express or implied.
166
167

170

One type

NEB. REV. STAT. § 28-448 (2001).
Id. The warning must state:
WARNING: Not intended for use by anyone under the age of 18. Do
not use this product if you are pregnant or nursing. Consult a health
care professional before using this product if you have heart disease,
thyroid disease, diabetes, high blood pressure, depression or other
psychiatric condition, glaucoma, difficulty in urinating, prostate
enlargement, or seizure disorder, if you are using a monoamine
oxidase inhibitor (MAOI) or any other prescription drug, or if you are
using
an
over-the-counter
drug
containing
ephedrine,
pseudoephedrine, or phenylpropanolamine (ingredients found in
certain allergy, asthma, cough/cold, and weight control products).
Discontinue use and call a health care professional immediately if you
experience rapid heartbeat, dizziness, severe headache, shortness of
breath, or other similar symptoms.

Id.
168

430 U.S. 519 (1977).
Id. at 525.
170
Id. A case on the October 2002 United States Supreme Court docket was
expected to clarify the implied preemption doctrine. Binh Ha Hong, Sprietsma, Rex
v. Mercury Marine, at http://www.medill.nwu.edu/cases.srch?-database=docket&layout=lasso&-response=/docket/detail.srch&-search&docket=01-0706 (last visited
Oct. 21, 2002) (on file with author). The case, Sprietsma v. Mercury Maine, was
decided on December 3, 2002. 123 S. Ct. 518 (2002). The question at issue was
“whether a state common-law tort action seeking damages from the manufacturer of
an out-board motor is [preempted] either by the enactment of the Federal Boat
Safety Act of 1971 [FBSA]” or by a 1990 Secretary of Transportation decision “not to
promulgate a regulation requiring propeller guards on motor boats.” Id. at 522.
The United States Supreme Court rejected the argument that “a need for regulatory
uniformity mandated a finding of federal preemption.” Trial Lawyers for Public
Justice, Supreme Court Holds that Injury Victims May Sue Boat Engine Manufacturers for
Failure to Install Propeller Guards, at http://www.tlpj.org/pressreleases/sprietsma_1203-02.htm (last visited Jan. 26, 2003) (on file with author). The Court, noting that
the express preemption clause in the FBSA did not include common-law claims,
169
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171

of implied preemption is field preemption. Field preemption exists
where the federal regulation in an area is “so pervasive as to make
reasonable the inference that Congress left no room for the states to
172
supplement it.” The second type of implied pre-emption is conflict
173
pre-emption.
Conflict pre-emption is present when a state’s law
“stands as an obstacle to the accomplishment and execution of the
174
full purposes and objectives of Congress.”
The DSHEA does not contain a general preemption clause, and
175
therefore, there is no express preemption.
When analyzing the
purposes of the enactment of the DSHEA, however, it is clear that the
federal government wanted to make dietary supplements more
accessible to consumers, and that Congress wanted the FDA to have
176
the power to act against dangerous dietary supplements.
State
action that hinders consumers’ ability to access these supplements
may be in opposition to the congressional objectives of availability,
and accordingly, it may be possible that these actions are subject to
177
preemption.
found that it “made sense for Congress not to [preempt] common-law claims, which
necessarily perform an important remedial role in compensating accident victims.”
Binh Ha Hong, Sprietsma Rex v. Mercury Maine, at http://journalism.medill.north
western.edu/docket/action.lasso?-database=docket&-layout=lasso&-response=%2F
docket%2Fdetail.srch&-recordID=33049&-search (last visited Jan. 26, 2003) (on file
with author).
171
Gade v. Nat’l Solid Waste Mgmt. Ass’n, 505 U.S. 88 (1992).
172
Rice v. Santa Fe Elevator Corp., 331 U.S. 218, 230 (1947).
173
Gade, 505 U.S. 88.
174
Florida Lime & Avocado Growers, Inc. v. Paul, 373 U.S. 132, 142-43 (1963).
175
Pinco & Rubin, Ambiguities of the Dietary Supplement Health and Education Act of
1994, 51 FOOD & DRUG L. J. 383, 397 (1996).
176
Id.; see also Dietary Supplement Health and Education Act of 1994, Pub. L. No.
103-417, sec. 2, 108 Stat. 4325, 4326 (Congressional Findings).
177
Pinco & Rubin, supra note 175, at 397; see also Dietary Supplement Health
and Education Act of 1994, Pub. L. No. 103-417, sec. 2, 108 Stat. 4325, 4326
(Congressional Findings). It is important to note that the federal government

plans to mandate its own particular warning labels for ephedra products,
thereby creating an even stronger preemption argument against state
warning label legislation. Ephedra: Government Urges Strongest Possible Warning
Labels for Ephedra Products, 6 No. 4 ANDREWS DRUG RECALL LITIG. REP. 8 (Nov.
2002). “Following a flurry of lawsuits against manufacturers of ephedrabased diet remedies and calls by consumer groups for tighter regulation of
such products, the [HHS] has ordered the [FDA] to generate the ‘strongest
possible mandatory warning label for ephedra products.’” Id. “Ephedrine,
an adrenaline-like neurostimulator, is the active ingredient in ephedra.”
Ephedra: Legal Troubles Mount for Maker of Ephedra Supplements, 18 No. 5
ANDREWS PHARMACEUTICAL LITIG. REP. 7 (Sept. 2002).
At present, there appear to be no federal regulations in direct conflict with the
state provisions discussed in Part III.A. There have been, however, attempts by the
federal government to regulate ephedrine products. See, e.g., Dietary Supplements
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C. Commerce Clause
178

The Commerce Clause may prohibit state regulation.
States,
under their police powers, have the power to regulate intrastate
179
commerce, even in a manner that will affect interstate commerce.
State legislation in this area must not, however, be protectionist in
180
nature.
When state legislation is aimed against interstate
commerce, the court will apply a two-part test to determine whether
Containing Ephedrine Alkaloids from Department of Health and Human Services,
Food and Drug Administration, 65 Fed. Reg. 17474 (withdrawal in part April 3,
2000). On April 3, 2000, the FDA announced that it was withdrawing specific
provisions of its proposed June 4, 1997 rule regarding dietary supplements that
contain ephedrine alkaloids. Id. This action was prompted by the Government
Accounting Office’s (GAO) concerns regarding the FDA’s basis for establishing the
proposed dietary ingredient level and the limit on duration of use. Id. The June 4,
1997 FDA proposed rule sought to establish when an ephedrine alkaloid containing
a dietary supplement would be deemed adulterated. Id. The proposed FDA
regulations were initiated “in response to reports of serious illnesses and injuries,
including a number of deaths, associated with the use of dietary supplement
products containing ephedrine alkaloids and the agency’s investigations and
assessment of these illnesses and injuries.” Id. The GAO agreed with the FDA that
attention and action against dietary supplements containing ephedrine alkaloids was
appropriate. Id. The GAO, however, “expressed concerns about the use of the
reported adverse events in supporting the proposed dosing level and duration of use
limit, and concluded that the agency needed additional evidence to support these
restrictions.” Id. The “GAO recommended that FDA ‘provide stronger evidence on
the relationship between the intake of dietary supplements containing ephedrine
alkaloids and the occurrence of adverse reactions that support the proposed dosing
level and duration of use limits.’ In addition, GAO recommended that FDA improve
the transparency of its cost-benefit analysis in its final rulemaking.” Id. These
conclusions, in addition to other comments on the proposed rules, prompted the
FDA to announce that certain aspects of the proposed rule should be reassessed. Id.
Therefore, the FDA withdrew the provisions of the proposed rule regarding the
ingredient level and duration of use limits. Id. The FDA plans to reevaluate whether
ingredient level and/or duration of use limits are appropriate, and will use public
input to assist in these determinations. Id. The FDA did not withdraw the provisions
concerning the “prohibition on the use of ingredients with stimulant effects with
dietary supplements containing ephedrine alkaloids (§111.100(d)) and the proposed
warning statement (§111.100(g)).” Id. The FDA did not at the time of this
announcement conclude whether it will finalize these two provisions.
178
U.S. CONST. art. I, § 8, cl. 3 (Commerce Clause). The Commerce Clause states
that Congress has the power “to regulate commerce with foreign nations, and among
the several States, and with the Indian tribes.” Id.
179
See United Nuclear Corp. v. Gen. Atomic Co., 629 P.2d 231, 270 (N.M. 1980)
(citing Merrill Lynch, Pierce, Fenner & Smith v. Ware, 414 U.S. 117, 140 (1973)); see
also Cities Serv. Co. v. Peerless Co., 340 U.S. 179, 186 (1950); Southern Pac. Co. v.
Arizona, 325 U.S. 761, 766-67 (1945); K.S.B. Tech. Sales v. North Jersey, 75 N.J. 272,
381 A.2d 774 (N.J. 1977)).
180
Philadelphia v. New Jersey, 437 U.S. 617, 626-27 (1978). The Court stated that
if a state enacted a “law that overtly blocks the flow of interstate commerce at a
State’s borders,” it would clearly be an example of economic protectionism. Id. at
624.
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181

such legislation may be upheld. This test requires the court first to
determine whether regulation’s “effects on interstate commerce are
182
only incidental.”
If the court determines that the effects are only
incidental, the regulation will be valid as long as the burden it creates
on interstate commerce is not “clearly excessive in relation to the
183
putative local benefits.”
State imposition of prescription status for particular products
may potentially create a burden on interstate commerce. For
example, granting products containing ephedrine prescription status
would restrict the ability of manufacturers to legally sell those
184
products to certain entities.
A state’s interest in protecting the
185
health of its citizens is a legitimate state interest. If a court finds the
burdens imposed on interstate commerce are more than incidental,
186
it will disallow the regulation. Conversely, the court applies the two-

181

See On petition for Review of Opinion 475 of the Advisory Committee on
Professional Ethics and DR 2102(C), 89 N.J. 74, 91,444 A.2d 1092, 1100 (N.J. 1982)
(upholding “regulations whenever (1) they are rationally to legitimate state
concerns, and (2) the resulting discrimination is outweighed by the state interest in
enforcing the regulation”).
182
United Nuclear, 629 P.2d 270 (citing Pike v. Bruce Church, Inc., 397 U.S. 137,
142 (1970)).
183
Id.
184
For example, in New Jersey,
[n]o person, who is not a registered pharmacist or an apprentice
employed in a pharmacy or drug store under the immediate personal
supervision of a registered pharmacist, or who is not a duly licensed
physician, dentist, veterinarian or other person licensed to prescribe
drugs shall sell, dispense, or furnish any drug the label of which by law
or regulations of the State Department of Health or Federal Food and
Drug Administration is required to bear a statement that it is to be
dispensed only by or on the prescription of a physician, dentist,
veterinarian or other person licensed to prescribe drugs, or words of
similar or like import; nor shall any registered pharmacist, or any
apprentice employed in a pharmacy or drug store under the
immediate personal supervision of a registered pharmacist, sell,
dispense, or furnish any such drug except upon the prescription of a
duly licensed physician, dentist, veterinarian or other person licensed
to prescribe such drug.
....
The provisions of this act shall not apply to the sale of any such drug by
a manufacturer or wholesaler or pharmacy to each other or to or by a
physician, dentist, veterinarian or other person licensed to prescribe
such drug in their professional practice.
N.J. STAT. ANN. § 45:14-26.1 (West 1995).
185
See Hughes v. Oklahoma, 441 U.S. 322, 337 (1979) (“We consider the States’
interests in conservation and protection of wild animals as legitimate local purposes
similar to the States’ interests in protecting the health and safety of their citizens.”).
186
See United Nuclear, 629 P.2d at 270 (citing Pike, 397 U.S. at 142).
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step balancing test if the burden is only incidental.
Additionally, other state actions, such as Nebraska’s statute that
requires specific warnings be affixed to labels, could be Commerce
188
Clause violations.
Separate labeling requirements imposed by
individual states may effect interstate commerce in a way that is not
merely incidental. It potentially could be too costly and burdensome
for manufacturers to meet each separate state’s labeling
requirements. Even if the court finds the burdens incidental, the
balancing test must be applied and the possibility exists that the
burdens would be found to outweigh the benefits of such
189
regulations.
As addressed above, state regulation of dietary supplements may
190
potentially create many problems. There may be preemption issues
191
Inconsistent
as well as possible Commerce Clause violations.
standards across the country can interfere with a manufacturer’s
ability to comply with all of them.
IV. ALTERNATIVES TO THE CURRENT DSHEA METHOD OF
REGULATION
The main problem with the current regulatory system is that
dietary supplements that are not approved prior to marketing are
readily available to consumers of all ages, despite the fact that they
pose potential health risks. Commentators have proposed numerous
solutions to this problem, ranging from congressional action to
192
stricter enforcement of the FDA’s goals and statutory regime. This
section will address the strengths and weaknesses of some of those
proposals, and will evaluate other possible solutions not yet proposed.
Additionally, the FDA and other organizations are presently taking
actions to fill some of the gaps that exist in dietary supplement
regulation; this section will address those actions and assess their
sufficiency.
A. Leaving the Present Scheme Unaltered
One possibility is to leave the scheme as it presently stands,
thereby encouraging states to continue to enact statutory law
restricting the availability of certain dietary supplements within their
187
188
189
190
191
192

See id.
See NEB. REV. STAT. § 28-448 (2001).
See United Nuclear, 629 P.2d at 270.
See supra PART III.B-C.
See id.
See, e.g., infra notes 196, 207, and 218.
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borders, if they desire a stricter scheme. As of now, state action has
been centered around restriction of, or total bans on, ephedrine and
193
ephedrine products.
Greater state regulation of dietary
supplements, however, threatens to impinge on at least one of
194
Congress’s goals in enacting the DSHEA—expanding availability.
States that choose to increase regulation in a manner that frustrates
195
Congressional goals may face a preemption challenge.
B. Pre-market Approval
A second possible solution is to require pre-market approval of
dietary supplements by requiring all manufacturers to submit
evidence of the safety and efficacy of the product to the FDA prior to
introducing it to the market, regardless of whether it has a “new
196
ingredient.” This solution would require legislative changes to the
197
present statute.
This approach ensures the safety of dietary
198
The
supplements by requiring proof of safety before marketing.
FDA would then have the opportunity to reject potentially dangerous
supplements before consumers can ingest them, and manufacturers
who know their products are unsafe would likely be reluctant to
spend time and money to attempt to obtain FDA approval when such
199
approval is unlikely.
This approach, however, may run in direct
opposition to the congressional goal of availability by imposing a
200
regulatory barrier prior to marketing.
Requiring dietary supplement manufacturers to test products
prior to marketing may create economic disincentives that discourage
201
manufacturers from producing supplements.
The testing and
approval process is expensive, and FDA approval is a time consuming

193

See generally PART III.A.
See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103417, sec. 2, 108 Stat. 4325, 4326 (Congressional Findings).
195
See PART III.B.
196
See Jeffrey A. Crossman, Note, “Sparing Cain: Executive Clemency in Capital Cases”:
Mark McGwire Does It, So Why Can’t I? High School Student Use of Dietary Supplements and
the Failure of the DSHEA, 28 CAP. U. L. REV. 617, 656 (2000) (suggesting that the FDA
should have the power to subject dietary supplements to the same standards and
requirements as are imposed on foods and drugs). For an explanation of these
requirements, see Crossman, supra, at 643-44.
197
See generally Dietary Supplement Health and Education Act of 1994, Pub. L. No.
103-417, 108 Stat. 4325 (codified as amended in scattered sections of 21 U.S.C.).
198
See Crossman, supra note 196, at 643-44, 656.
199
See id.
200
See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103417, sec. 2, 108 Stat. 4325, 4326 (Congressional Findings).
201
See Kaiser, supra note 15, at 1260.
194
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202

process.
Drug manufacturers are economically capable of
complying with pre-market clearance requirements because by
patenting their drug they can secure income for profits and
203
research.
Herbal supplement manufacturers do not have the
economic protection that a patenting system would afford, and
accordingly, do not have the same financial capabilities to comply
204
with pre-market clearance requirements as do drug manufacturers.
If a system of patenting could be fashioned for dietary supplements, it
would give manufacturers an opportunity to recover the funds
205
expended in initial testing for safety.
C. Creating “New” Ingredient Lists
One means by which the FDA could regain some control over
what enters the market involves compiling a list of dietary ingredients
that are not “new” within the relevant definition of the word. It
arguably should not be the manufacturer’s responsibility to
determine whether its product contains a “new” ingredient, because
the manufacturer has an interest in determining that the ingredients
206
in their supplement are not in fact “new.” The FDA could compile
this list and include all ingredients that the FDA would not consider
“new,” thereby eliminating the manufacturer’s power to determine
whether or not its product contains a “new” ingredient. The FDA,
however, may be better served expending its resources trying to find
dangerous supplements, rather than by relieving manufacturers from
the burden of making this determination.
D. Increasing Manufacturer Responsibilities
An alternative solution involves a change in the reporting system
that requires all dietary supplement manufacturers report to the FDA
207
any side effects or adverse events linked to the use of a supplement.
If manufacturers informed the FDA of side effects and adverse events,

202

Id. Manufacturers can expect to spend $2,000,000 on the process, and
subsequently will have to wait two to six years to gain approval from the FDA. Id.
203
Sonia Sequeira, Drug Rules Under Spotlight at WTO, at http://www.cnn.com/
2001/WORLD/europe/11/08/wto.trips/ (Nov. 8, 2001) (on file with author).
204
Zuk, supra note 119, at 38.
205
Schindler, supra note 14, at 279-80.
206
See DSHEA Website, supra note 26 (describing the additional requirements
when introducing a “new dietary ingredient” to the market).
207
Robert Hager, Unsafe Supplements?, at http://www.msnbc.com/news/55761
8.asp (Apr. 10, 2001) (on file with author). In Appendix C of the HHS Report, the
FDA noted that it is “evaluating whether or not such a reporting could be required
under current law.” HHS Report, supra note 2, at 41.
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the FDA could evaluate the risks and alert consumers when
208
This procedure is already required of pharmaceutical
necessary.
manufacturers; adverse events for prescription drugs and for some
209
over-the-counter drugs must be reported.
This would allow the
FDA access to more information, and accordingly, would help the
210
FDA inform consumers and act against unsafe supplements. It may
be difficult, however, for the FDA to ensure manufacturers are
211
complying with this reporting requirement.
Alternatively, the FDA could compel manufacturers to register
212
the dietary supplements they place on the market.
The
implementation of such a registration requirement would necessitate
a legislative change in the DSHEA, and the commitment of
213
additional resources. Presently, the FDA has difficulty determining
214
what ingredients are in each supplement, therefore, along with this
registration, the manufacturer should be compelled to provide a list
215
This could assist the
of all of the ingredients in the supplement.
FDA in following up on adverse reports. When the FDA receives
adverse reports, it would have the manufacturer’s name and contact
information, along with the supplements it sells and the ingredients
216
in each supplement.
A registration system would give the FDA
217
sufficient information to act quickly on adverse event reports.
E. Germany’s Approval System
At least one commentator has suggested establishing a system
218
similar to that used in Germany.
In Germany, prior to marketing
an herbal remedy, safety and “reasonable proof” of efficacy of the

208

Id.
HHS Report, supra note 2, at 19.
210
See id. (suggesting a requirement that manufacturers report adverse events in
order to “facilitate greater detection of adverse events”).
211
Id.
The HHS report goes on to suggest the FDA should convince
manufacturers of the importance and adequacy of such a system in order to promote
compliance. Id.
212
Id.
213
Id. at 25.
214
EXECUTIVE BRIEFING, supra note 68.
215
Hager, supra note 207.
216
HHS Report, supra note 2, at 20-21.
217
See id. at 20 (noting that requiring “dietary supplement manufacturers to
register their products with the FDA” would “improve the quality and quantity of . . .
product information” and therefore “generate stronger signals of public health
concerns”).
218
Stenson, supra note 4.
209
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219

product must be established.
Germany has an independent panel
of medical experts with the responsibility of reviewing different
220
herbal remedies and evaluating their efficacy and safety. This panel
also has the responsibility of creating monographs for some of these
221
herbal remedies.
A product meets its burden of proof when the
222
panel gives an indication in a monograph. This standard is not as
stringent as the FDA’s standard for the entrance of drugs and food
223
additives into the market. It does, however, impose some entrance
requirements prior to marketing, unlike the current DSHEA
224
regime.
F. Changes in Enforcement
Yet another improvement to the current system involves a
change in enforcement. As mentioned in Part I, the FDA often
requests samples from manufacturers when investigating an adverse
event report, and more often than not, manufacturers fail to
225
comply.
FDA sanctions for noncompliance would possibly enable
the FDA to follow up on adverse event reports more efficiently and
thoroughly. This method would also give the FDA a greater ability to
warn consumers of potentially harmful supplements on the market.
Without imposing sanctions, the trend of manufacturers failing to
comply with these requests may be difficult to change.
G. Additional Research
Additional safety research on dietary supplements would likely
226
help to improve the current system. If the FDA conducted its own
studies, or funded independent studies, the results would increase
227
the FDA’s access to information. This information could be used to
“adequately assess signals generated by the adverse event reporting
219

Tolstoi, supra note 52.
Stenson, supra note 4; see also Tolstoi, supra note 52.
221
Tolstoi, supra note 52. “Monographs are point papers on particular products
or ingredients that contain safety and efficacy information.” HHS Report, supra note
2, at 22.
222
Tolstoi, supra note 52.
223
Id.
224
Id.
225
EXECUTIVE BRIEFING, supra note 68.
226
HHS Report, supra note 2, at 22. The HHS Report recommends a
collaboration with the NIH in “setting a research agenda addressing safety issues” in
order to “increase the quality and quantity of clinical data” in order to “obtain vital
information to adequately assess signals generated by the adverse event reporting
system.” Id.
227
Id.
220
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system.”
There are currently some federally funded studies on
229
The process of researching and
dietary supplements in progress.
analyzing results, however, is a time consuming and costly project,
and it may not be feasible for the FDA or the government to fund this
alone. Commentators have suggested the creation of a compulsory
system where supplement manufacturers contribute money, based on
230
their market share, to a fund to pay for clinical trials.
This would
benefit consumers because studies would be conducted, and would
benefit manufacturers because they would not carry the burden of
231
paying for individual studies.
Requiring manufacturers to
contribute money for use in clinical trials, however, may discourage
232
manufacturers from producing these products.
Without a patent
process for herbal supplements, these research costs would be
imposed upon manufacturers without providing economic safeguards
233
to make such investments less financially risky.
The DSHEA originally allotted $5 million annually for the ODS;
however, the ODS is consistently underfunded, receiving
234
approximately one-fifth of the allotted amount.
The absence of
sufficient funding has prevented the ODS from being able to address
235
individual inquiries and has limited its research abilities.
One
commentator argues that the ODS can increase consumer protection
by distributing information, but only if the ODS is given adequate
236
funding and staffing. If the ODS were adequately funded, it would
have the ability to obtain information on the beneficial and
dangerous aspects of dietary supplements and inform consumers of
237
these aspects.
Although research on different fronts is arguably helpful in
attaining supplement information, there is a sound argument that
the manufacturer, and not the taxpayer, should be responsible for all
of the costs of research because it is the manufacturer who ultimately
profits from the sale of these supplements. The research and
evaluation of the results would provide vital information regarding

228
229
230
231
232
233
234
235
236
237

Id.
Stenson, supra note 4.
Termini, supra note 13, at 286.
Id.
See supra notes 202-05.
Id.
Sloane, supra note 9, at 337.
Id.
Id. at 339.
Id.
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238

these dietary supplements.
If there is sufficient information to
educate manufacturers, the FDA, and consumers, there may be no
239
need to create a stricter scheme for dietary supplements.
Part of
the problem is that not enough is known about the dangers of these
240
products. If such dangers were identified, the FDA would arguably
be better equipped to determine whether a dietary supplement is
“adulterated,” and could then react within their present DSHEA
241
powers.
H. Current Efforts
One goal of the Ten Year Plan involves establishing GMPs for
242
dietary supplements.
The FDA is working to establish GMPs for
dietary supplements, which will help to both standardize dietary
243
supplements and improve their quality.
HHS has recommended
the creation of GMPs to help prevent contamination of
244
GMPs would lessen some of the dangers of dietary
supplements.
245
supplements, such as contamination and differences in strength.
The GMPs alone, however, would not be an effective remedy because
246
Supplements may
they do not test the safety of the supplement.
have inherently dangerous side effects or interactions with other
247
drugs, and GMPs would not address this problem. Yet, GMPs would
be a valuable tool, especially if used in combination with other
methods aimed at the inherent dangers of supplements.
A national certification system designed for dietary supplements
248
is another alternative. The United States Pharmacopeia (“USP”) is
249
initiating a pilot program for such a certification system. The USP
presently sets standards for prescription and over-the-counter
238

See HHS Report, supra note 2, at 22-23.
See id. at 22 (noting that “[p]erhaps the largest problem the FDA faces is the
paucity of scientifically robust research on dietary supplements that is available in the
event that a particular supplement product or ingredient generates a signal of
possible public health concern”).
240
Id.
241
See PART I, for a discussion of the FDA’s present DSHEA powers.
242
TEN YEAR PLAN, supra note 107. Section I.B. states that a CFSAN goal is to
publish good manufacturing practices, and once issued, to “establish an outreach
program to small business manufacturers and an ongoing inspection program.” Id.
243
Stenson, supra note 4.
244
Hager, supra note 207.
245
See Stenson, supra note 4.
246
See id.
247
For examples of such dangers, see supra note 46.
248
Stenson, supra note 4.
249
Id.
239
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250

medications.
Once the national certification system is established
for dietary supplements, manufacturers that meet the necessary
requirements would be allowed to place a certification mark on their
251
product labels.
This certification mark would be a sign to the
consumer that the products are of a particular quality and that they
252
contain only the ingredients on the label. This process would help
consumers choose dietary supplements, however, as the HHS Report
notes, this system would have limited capability to protect consumers
because “it would be voluntary; it would not address botanicals’
health claims or safety issues, and United States Pharmacopeia would
253
not enforce adherence to these standards.”
I. Broadening the FDA’s Power to Act Against Supplements
Some argue that the FDA’s power should be broadened in the
254
area of dietary supplement regulation.
One suggestion is that the
FDA could better regulate in this area if given wider powers once a
health threat is discovered, without altering the present scheme to
255
require pre-market clearance.
Under this scheme, once a health
threat is found, the FDA should have the power to force ingredient
256
This
changes, or pull the product from the market completely.
differs from the present regulatory scheme, which requires the FDA
to bear the burden of proving that the product presents “a significant
or unreasonable risk of illness or injury” prior to taking action against
257
it.
Another suggestion is to empower the FDA to act against an
entire supplement class, broadening its current powers which only
258
permit the FDA to act against individual products. These broader
powers would be highly advantageous because the FDA would have
the ability to act simultaneously against many supplements that pose
259
the same risk, instead of going after one at a time.

250
251
252
253
254
255
256
257
258
259

Id.
Id.
Id.
HHS Report, supra note 2, at 23.
See, e.g., Kaiser, supra note 15, at 1273.
Id.
Id.
21 U.S.C. § 342 (f)(1)(A) (2002).
Kaiser, supra note 15, at 1273.
See id.
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J. Burden Shifting Through Legislative Change
A different proposal is to treat dietary supplements as food
260
additives.
This would require a change in the law, and would
broaden the FDA’s power by eliminating its burden of proving a
261
With this method of regulation, if the FDA
product unsafe.
determines that a supplement is unsafe, the manufacturer would
262
then bear the burden of proving that the product is safe. To gain
admission to the market, this system would require proof of safety,
263
but not efficacy. A similar approach would be to change the statute
264
to require manufacturers to “substantiate the safety” of its products.
This would be helpful to the FDA in its enforcement efforts because
the burden of proving a product’s safety is shifted to the
265
manufacturer. These processes would help protect consumers from
dangerous products, however, any proposed change of the statute
giving the FDA greater power would possibly face lobby efforts from
266
the powerful supplement industry.
K. Granting Prescription Status to Particular Supplements
A final solution is to give certain dietary supplements
267
prescription status, as some states are doing with ephedrine.
Product classes that pose a serious threat when taken as directed, that
may be improperly used, or that have serious interactions with
268
medications, could be given prescription status.
Granting these

260

Schindler, supra note 14, at 280.
Id.
262
Id.
263
Id.
264
Gilhooley, supra note 33, at 128. Professor Gilhooley notes that “[a] major
weakness in the DSHEA is that it does not impose on all dietary supplements the
burden and obligation to affirmatively substantiate their safety.” Id. Professor
Gilhooley explains that “[i]f manufacturers had to substantiate safety, they would
have to perform tests, in accordance with scientific standards, to determine risks and
establish a safe level. They would have a responsibility to follow-up on adverse
reaction reports, and undertake whatever testing or changes scientists would
consider necessary to assure safety.” Id. at 119.
265
See id. at 128.
266
See Colloton, supra note 27, at 496-97 (noting the enormity of the dietary
supplement industry, and stating that “[p]rior to the DSHEA, the dietary supplement
industry and consumers struggled for decades with the U.S. Food and Drug
Administration (“FDA”) in an effort to increase public access to both supplements
and information regarding the benefits of supplements”).
267
See, e.g., TENN. CODE ANN. § 39-17-431 (1995); LA. REV. STAT. ANN. § 40:962.1
(West 1995); MINN. STAT. ANN. § 152.135 (West 1998).
268
See, e.g., PART III.A. (discussing how some states have made ephedrine available
only by prescription).
261
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products prescription status would provide a greater opportunity for
consumer education through the prescribing physician, the
pharmacist, and the labeling and information provided by the
269
pharmacy.
When evaluating whether a supplement is adulterated,
and therefore whether the FDA has authority to take action against it,
the FDA looks at the safety when taken as the label directs, or in the
270
absence of such directions, under normal use.
Perhaps the FDA,
however, should look at the health threat when taken in excess of the
specific dosage directions to determine whether additional steps
271
should be taken and whether prescription status should be granted.
This approach might make it more difficult for consumers to access
certain supplements, and accordingly would run counter to one of
272
the purposes of the DSHEA—greater availability.
Requiring a
consumer to obtain a prescription, however, is not as restrictive as
completely removing a product from the market. Additionally,
imposing prescription status when necessary would further
273
Congress’s goal of preventing the sale of dangerous supplements.
L. Proposed Solution
The solution best suited for this situation would appear to be a
combination of changes designed to improve the safety of dietary
supplements without unduly hindering Congress’s goal of increasing
274
the availability of dietary supplements.
To achieve this balance,
three regulatory changes must be made. First, Congress must shift
the burden of proving a product’s safety onto the manufacturer, even
275
if pre-market approval is not required. When the FDA wants to take
269

For example, a pharmacist may be required to counsel patients on their
prescription medications. See, e.g., Arkansas State Board of Pharmacy, Consumers –
Did You Know?, at http://www.state.ar.us/asbp/public.html (last visited Oct. 22,
2002) (on file with author). This website states that the pharmacist “should counsel
you regarding your prescription,” “should tell you about any side effects of the drug
or any interaction that it might have with other drugs you are taking,” and “should
give you instructions regarding when you should take the medicine and if it should
be taken with food.” Id.
270
DSHEA Website, supra note 26.
271
Jennifer Spokes, Note, Confusion in Dietary Supplement Regulation: The Sports
Product Irony, 77 B.U. L. REV. 181 (1997) (pointing out that products that are
dangerous in excess of the dosage directions are excluded from the definition of
adulteration).
272
See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103417, sec. 2, 108 Stat. 4325, 4326 (Congressional Findings).
273
Id.
274
Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417,
sec. 2, 108 Stat. 4325, 4326 (Congressional Findings).
275
Schindler, supra note 14, at 280; see also Gilhooley, supra note 33, at 128.
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action against a product, it should not first bear the burden of
proving it unsafe; instead, the manufacturer should bear the burden
276
of proving that the product at issue is safe. The FDA should then
examine the data on which the manufacturer relies, and take action
if the data is insufficient to demonstrate the product’s safety. Second,
Congress should amend the DSHEA to grant the FDA power to act
against a dietary supplement class, as opposed to against each
277
individual dietary supplement. If the FDA is acting against a class of
products, it may be appropriate for manufacturers to prove product
safety as a class, and divide researching and other costs incurred in
making these proofs. Third, supplements that are found to be
dangerous in doses larger than that suggested on the label, if these
higher doses are likely to be used despite warnings, should be
278
granted prescription status on the federal level. Prescription status
would help curb dangers of these products without completely
withdrawing them from the market.
These regulatory changes would increase the FDA’s ability to
police the dietary supplement market, and would only interfere with
the sale of potentially dangerous supplements. This combination
approach does not unduly limit the availability of dietary
supplements, while still protecting consumers.
The FDA’s present research efforts, along with research efforts
of other organizations such as the NIEHS and the ODS, should be
279
continued.
Research can significantly assist the FDA in
determining which dietary supplements are potential risks, thereby
280
The ODS should
enabling the FDA to take appropriate action.
receive funding equivalent to, or greater than, the original amount
281
granted in the DSHEA.
GMPs and USPs are valuable in ensuring
the quality, purity and strength of dietary supplements, and should
282
be established.
Research, GMPs, and USPs, combined with the suggested
regulatory modifications, will help ensure that products on the
market are not contaminated and are not misbranded. This will also
provide the FDA with a greater opportunity for questioning, limiting
276

See Gilhooley, supra note 33, at 128.
Kaiser, supra note 15, at 1273.
278
As discussed previously, some states are already doing this with ephedrine. See,
e.g., TENN. CODE ANN. § 39-17-431 (1995); LA. REV. STAT. ANN. § 40:962.1 (West
1995); MINN. STAT. ANN. § 152.135 (West 1998).
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See, e.g., PART I.D.
280
HHS Report, supra note 2, at 22.
281
See Sloane, supra note 9, at 337.
282
FDA Overview Website, supra note 49; see also Stenson, supra note 4.
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and removing dangerous products from the market.
CONCLUSION
Dietary supplements are freely available to consumers, and are
283
placed on the market with minimal regulation. Approximately sixty
284
Some dietary
percent of Americans take dietary supplements.
supplements have potentially dangerous side effects, and have been
285
shown to interact with prescription medications. These dangerous
side effects and interactions are largely discovered after the harm has
occurred, because of the manner in which the current system
286
operates.
Additionally, once the FDA determines a dietary
supplement poses a potential threat, the DSHEA limits the FDA’s
power and assigns burdens in such a way as to hinder the FDA’s
ability to promptly and effectively eliminate such dangers to
consumers. A change in this system is necessary. Allowing the
marketing of these potentially dangerous supplements until sufficient
harm is reported by consumers, while hindering the FDA’s ability to
act against potentially dangerous supplements, is unacceptable—
consumers need greater protection.

283
284
285
286

See generally PART I.
HHS Report, supra note 3.
See supra note 46 (describing potential side effects of dietary supplements).
See generally PART I.B.

